RxDoctor Payments Data

Alfonso Gonzalez-Rodriguez

Internal Medicine · Orlando, FLNPI 1629091384

Payments from drug & device makers

What this record shows

18 manufacturers reported payments, led by CSL Behring at 33.0% of the total. Reporting peaked in 2024 at $3,432 and has fallen 68.3% since, to $1,088 in 2025. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,748in general payments, 2019–2025

Across 92 payments — averaging $62.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$2K
  • Merck$1K
  • Novartis$978
  • Johnson & Johnson$577
  • Sunovion Pharmaceuticals Inc.$161
  • Abbott$146
  • plus $888 from 12 others
$4,736,803in research payments, 2019–2025

Across 546 payments — averaging $8675.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$2.1M
  • Modernatx, Inc.$714K
  • Boehringer Ingelheim International GmbH$472K
  • Eli Lilly$360K
  • Pfizer$329K
  • AstraZeneca$175K
  • plus $584K from 9 others

What the payments were for

  • Travel & lodging$3,29657%
  • Food & beverage$2,45243%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,748 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$8,590
XareltoRivaroxaban30$8,358
EntrestoSacubitril/Valsartan24$4,050
Gabapentin56$1,247
Levetiracetam26$1,198
Atorvastatin Calcium50$1,151
Montelukast Sodium46$1,037
Donepezil Hcl28$844
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$786
Tamsulosin Hcl35$714
Humalog Kwikpen U-100Insulin Lispro14$655
Amlodipine Besylate52$619
Metoprolol Tartrate44$576
Hydralazine Hcl29$524
Metformin Hcl40$481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$577$8,35830 claims
NovartisEntresto$978$4,05024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →